Fatty acids (FAs) are important as metabolic substrates and as structural components of biological membranes. However, they also function as signalling molecules. Recently, a series of G protein-coupled receptors (GPRs) for FAs has been described and characterized. These receptors have differing specificities for FAs of differing chain length and degree of saturation, for FA derivatives such as oleoylethanolamide, and for oxidized FAs. They are a critical component of the body's nutrient sensing apparatus, and small molecule agonists and antagonists of these receptors show considerable promise in the management of diabetes and its complications. Agonists of the long-chain free fatty acid receptors FFAR1 and GPR119 act as insulin secretagogues, both directly and by increasing incretins. Although, drugs acting at short-chain FFA receptors (FFAR2 and FFAR3) have not yet been developed, they are attractive targets as they regulate nutrient balance through effects in the intestine and adipose tissue. These include regulation of the secretion of cholecystokinin, peptide YY and leptin. Finally, GPR132 is a receptor for oxidized FAs, which may be a sensor of lipid overload and oxidative stress, and which is involved in atherosclerosis. Regulation of its signalling pathways with drugs may decrease the macrovascular risk experienced by diabetic patients. In summary, FA receptors are emerging drug targets that are involved in the regulation of nutrient status and carbohydrate tolerance, and modulators of these receptors may well figure prominently in the next generation of antidiabetic drugs.
Introduction
The first three decades of the third millennium will see a doubling in global prevalence of diabetes to over 350 million. The resulting morbidity and premature mortality from microvascular, macrovascular and other complications is driving research into the underlying mechanisms and the quest for nutritional and pharmacological interventions. The role of free fatty acids (FFAs) in glycaemic regulation and type 2 diabetes pathogenesis is well established [Bergman and Ader, 2000] , but the recent identification of a family of G protein-coupled receptors (GPRs) whose natural ligands are fatty [Stoddart et al. 2008; Covington et al. 2006 ] has awakened interest in how the effects of fatty acids (FAs) are mediated and has alerted us to the possibility of new therapeutic approaches. The recent demonstration that palmitoleate (C16 : 1n7) secreted by adipose tissue enhances insulin sensitivity in other tissues lends further stimulus to the study of messenger functions of FAs [Cao et al. 2008] . In this review, we discuss what is known about FA receptors, and speculate on how modulation of these signalling pathways may help lessen the burden of diabetes and its complications.
A family of GPRs for FFAs
The majority of signalling across cell membranes occurs following the binding of messengers to their cognate receptors. In most cases, receptor activation is coupled to proteins with GTPase activity (G proteins) which, in turn activate or inhibit intracellular messengers [Millar and Newton, 2010] . The a subunits of G proteins differ in ability to modulate pathways: Ga s , activation leads to increased cyclic adenosine monophosphate (cAMP); Ga i/o , inhibition of cAMP production; Ga q/11 , by activating phospholipase C, increases inositol-1,4,5-trisphosphate, which increases cellular calcium and also diacylglycerol, which activates protein kinase C; this Ga subtype is pertussis toxin sensitive; Ga q12/13 , activates the Rho family of GTPases. The human genome contains over 800 GPRs divided into five families (i.e. rhodopsin, secretin, adhesion, glutamate and taste). GPRs mediate the effect of about one third of the drugs in current use. The family of receptors for FFAs, which belong to the rhodopsin family, are summarized in Table 1 . Like other GPRs, these are proteins of 300400 amino acids comprising an extracellular domain, seven transmembrane loops and an intracellular domain. The receptors have specificities for FAs of differing chain length. GPR119 is included here although its ligand is oleoylethanolamide (OEA), an FA derivative rather than an FFA. The FFA receptors form part of the body's nutrient sensing apparatus, which includes the gastrointestinal tract, pancreas, adipose tissue, leucocytes and parts of the central nervous system. Unlike the classic 'lock and key' relationship between receptors and their ligands, nutrient receptors are considered to be promiscuous in that they can be activated by a range of ligands [Wellendorph et al. 2009 ].
FFAR1 (GPR40)
FFAs stimulate insulin secretion acutely, but chronic elevation leads to lipotoxicity with decreased b-cell function and peripheral insulin resistance. FFAR1 may be involved in both effects, and it remains controversial whether FFAR1 agonists or antagonists are most likely to be useful pharmacologically [Morgan and Dhayal, 2009; Brownlie et al. 2008] . FFAR1 was described independently by three groups [Briscoe et al. 2003; Itoh et al. 2003; Kotarsky et al. 2003 ]. The receptor is activated by medium-and long-chain saturated and unsaturated FAs [Ichimura et al. 2009 ]. Pentadecanoic (C15) and palmitic (C16) acids are the most potent saturated ligands, while chain length and degree of saturation are not major determinants of receptor affinity for unsaturated FAs. The most important sites for FFAR1 expression are the insulin-secreting b cells, the K and L cells of the small and large intestine respectively, splenocytes and peripheral blood mononuclear cells [Morgan et al. 2009; Parker et al. 2009] . FFAR1 is also expressed in the a cells in the pancreatic islets, where it is involved in regulating glucagon secretion in response to unsaturated FAs [Flodgren et al. 2007] . Although expressed in areas of the central nervous system, including the hippocampus, its role is not known at present [Ma et al. 2008] . The EC50 for receptor activation is in the micromolar range, while the FFA is probably in the nanomolar range physiologically (most FAs being bound to albumin). It has thus been difficult to assess the physiological significance of FFAR1 activation in vivo. Local generation of FFAs by lipoprotein lipase may increase local FFA delivery.
Steneberg and colleagues reported that mice deficient in FFAR1 are protected from obesityinduced hyperinsulinaemia, dyslipidaemia and glucose intolerance, while overexpression of the receptor leads to hyperinsulinaemia and glucose intolerance [Steneberg et al. 2005] . However, subsequent studies [Morgan and Dhayal, 2009] have not suggested that FFAR1 knockdown has a major protective effect. Recently developed small molecule antagonists such as DC260126 may not, therefore, be useful in the treatment of diabetes. It now seems that agonists and not antagonists may prove to be of greater clinical use [Bharate et al. 2009; Brownlie et al. 2008; Kebede et al. 2008] , which is consistent with [Nagasumi et al. 2009 ]. The receptor can be activated by thiazolidinedione drugs, as well as FFAs [Kotarsky et al. 2003] . A small molecule agonist (GW9508) of FFAR1 and GPR120 has been described ]. Both GW9508 and linoleic acid increased intracellular calcium in HEK-293 cells transfected with FFAR1, and GW9508 also enhanced insulin secretion from MIN6 cells. Christiansen and colleagues described a series of 4-phenethynyldihydrocinnamic acid derivatives that were FFAR1 agonists and also could act as insulin secretagogues [Christiansen et al. 2008] . A series of diacylphloroglucinol compounds with FFAR1 agonist activity has also been studied [Bharate et al. 2008] . There are also prospects for altering receptor activation by limited genetic manipulations [Sum et al. 2009 ]. None of the above insulin secretagogues has yet reached the stage of being subjected to human clinical trials.
FFAR2 (GPR43)
One of a cluster of FA receptor genes located at chromosome 19q13.1, FFAR2 is preferentially activated by propionate and is coupled to both Ga i/o and Ga q/11 . FFAR2 is highly expressed in leucocytes, and may have a role in the differentiation and activation of monocytes and polymorphonuclear cells. It is not known whether these actions are relevant to diabetes although patients with diabetes have increased monocyte activation and this is a precursor to tissue infiltration (including adipose and the arterial wall) and their subsequent differentiation into macrophages. These processes are important in regulating the low-grade inflammation that accompanies obesity and in atherogenesis. FFAR2 is also expressed in the L cells of the ileum and colon [Karaki et al. 2006 ]. These entero-endocrine cells synthesize and secrete peptide YY. The latter is known to be increased in response to shortchain FAs [Cherbut et al. 1998 ], and its release is accompanied by decreased appetite and decreased food intake through actions in the central nervous system [Batterham et al. 2003 ]. Short-chain FAs are produced in the gut by microbial fermentation of indigestible carbohydrate. Using probiotics, the gut flora can be altered and this has recently been proposed as a means of regulating appetite, decreasing insulin resistance and decreasing risk of nonalcoholic fatty liver disease [Musso et al. 2010 ]. Use of probiotics increases intestinal release of glucagon-like peptide (GLP)-1 and GLP-2 (incretins) and also peptide YY [Musso et al. 2010; Cani et al. 2009 ]. Finally, FFAR2 has been reported to be expressed in adipocytes, and its expression upregulated in mice fed a high fat diet [Hong et al. 2005 ]. Silencing of the FFAR2 gene using siRNA interfered with adipocyte differentiation in the 3T3-L1 cell line. These authors did not detect FFAR3 (GPR41) in adipose tissue or 3T3-L1 cells. In our hands, FFAR3 is highly expressed in 3T3-L1 preadipocytes and adipocytes, while FFAR2 is only expressed in fully differentiated cells. Ge and colleagues reported that FFAR2 activation decreased lipolysis in vivo, an effect that was not present in FFAR2 knockout mice [Ge et al. 2008] . Furthermore, in vivo FFAR2 activation decreased plasma FFA levels. Clearly, FFAR2 activation could improve some features of metabolic syndrome. However, as with thiazolidinediones, this may be achieved by decreasing circulating FFAs through increased adipocyte differentiation and thus increased levels of adiposity. Lee and colleagues described a number of small molecule phenylacetamides that acted as selective allosteric agonists at FFAR2 [Lee et al. 2008] . The synthetic ligands were more potent than endogenous ligands (acetate and propionate), and treatment of adipocytes with these agonists inhibited lipolysis. [Djousse et al. 2009 ]. The effect of ethanol ingestion, which increases circulating acetate, to improve glucose homeostasis is due to effects on both insulin production and insulin sensitivity [Player et al. 2010; Hafko et al. 2009] . In a recent study [Gao et al. 2009] , butyrate administration to mice led to improved systemic insulin sensitivity. Furthermore, shortchain FAs directly stimulate differentiation of stem cells into insulin-secreting b cells [Ren et al. 2010; Li et al. 2008] . Butyrate has long been known to influence adipocyte maturation, and this was presumed to be due to its action as a histone deacetylase (HDAC) inhibitor. Recent data, however, suggest that butyrate enhances adipogenesis while other HDAC inhibitors attenuate the process [Kim et al. 2009 ]. Finally, fermentation of complex carbohydrates in the colon yields very high local levels of short-chain FAs but also increases circulating short-chain FA levels. Recent studies demonstrate that administration of complex carbohydrates improves the lipid profile, decreases postprandial FFA excursions, improves insulin sensitivity and increases circulating GLP-1 [Freeland et al. 2010; Priebe et al. 2010; Tarini and Wolever, 2010; Queenan et al. 2007] . It is hard to imagine that FFA receptors are not relevant to the above physiological and clinical observations. FFAR1 and FFAR2 may be expressed in b cells [Covington et al. 2006] , although this has only been alluded to in patent applications and the suggestion is not supported by peer-reviewed publications.
GPR84
This receptor for medium-chain FFAs is highly expressed on immune cells and is activated particularly by capric (C10), undecanoic (C11) and lauric (C12) acids [Ichimura et al. 2009] . There are at present no data to support a role for this receptor in nutrient balance, and pharmacological modulators have not been described. Medium-chain triglycerides and FAs decrease energy intake (probably through actions on hepatic intermediary metabolism) [Ooyama et al. 2009; de Sousa et al. 2006 ]. However, we cannot assume that this is GPR84 mediated since the effects of medium-chain FAs on immune cell activation are not mediated by GPR84 [Versleijen et al. 2009 ].
GPR119
Although not strictly an FFA receptor, GPR119 is considered here because its natural ligands are FA derivatives and there is a real prospect for receptor agonists to be used for diabetes treatment [Overton et al. 2008] . GPR119 is highly expressed on the pancreatic b cell where agonists act as insulin secretagogues. The natural ligand is OEA (Figure 1 ) [Overton et al. 2006 ], an analogue of the cannabinoid anandamide. OEA is an activator of peroxisome proliferator-activated receptor (PPAR)-a, and systemic administration of OEA decreases feeding and body weight. Lysophosphatidylcholine (LPC) is also an endogenous ligand. Both OEA and LPC are produced by cell surface phospholipases in a variety of tissues including the small intestine.
Chu and colleagues showed that the GPR119specific agonist AR231453 increased cellular cAMP and insulin release in HIT-T15 cells and in rodent islets [Chu et al. 2007 ]. The agonist was inactive when the GPR119 gene was silenced. AR231453 increased insulin release and improved glucose tolerance in wild-type mice and diabetic KK/A(y) mice. In a further study [Chu et al. 2010] , they screened a series of lipid amides for the ability to activate GPR119 in cells transfected to express the receptor. N-oleoyldopamine (OLDA), an endovanilloid, proved to be as potent an activator as either OEA or AR231453. Therapeutic Advances in Endocrinology and Metabolism 1 (4) Furthermore, OLDA enhanced secretion in insulin-producing cells and also improved glucose tolerance when administered orally to mice. There was no response when OLDA was administered to GPR119-deficient mice. Synthetic GPR119 agonists share a common mechanism of action to OEA but some agents may additionally activate other pathways in insulin-secreting cells [Ning et al. 2008] .
GPR119 is also expressed in entero-endocrine cells, which secrete glucose-dependent insulinotropic peptide (GIP) or GLP-1, and OEA signalling through GPR119 leads to increased GLP-1 secretion from these cells [Lauffer et al. 2009 ]. Administration of AR231453 increases secretion of both incretins, contributing to improved glucose tolerance in mice [Chu et al. 2010 [Chu et al. , 2008 . Release of GLP-1 and improved glucose tolerance was further enhanced when AR231453 was administered along with the dipeptidyl peptidase-IV inhibitor sitagliptin [Chu et al. 2010] . While GPR119 is the mediator for the insulin secretory and incretin effects of OEA, recent experiments with GPR119 knockout mice suggest that the receptor does not mediate the appetite-suppressing effects [Lan et al. 2009 ]. GPR119 agonists represent an exciting new class of agents with considerable potential to improve glucose tolerance. Several agents of this class are now in phase 1 clinical trials [Jones et al. 2009; Shah, 2009; Semple et al. 2008] . Although GPR119 may not mediate the central effects of lipid mediators on energy homeostasis, it may well be that the orally active agonists help preserve b cells, either directly, or indirectly by increasing levels of GIP and GLP-1 [Overton et al. 2008] .
GPR120
This receptor shares only 10% sequence homology with FFAR1, and is optimally activated by saturated FAs of chain length 1418 and unsaturated FAs of chain length 1622. GPR120 is expressed in monocytes, adipocytes and various cells of the gastrointestinal tract. The role of the receptor in immune cells is not known. In our hands, GPR120 expression decreases on monocyte activation while expression of the oxidized FA receptor GPR132 (described in the following) increases. GPR120 is expressed during adipocyte maturation and may have a role in regulating adipogenesis [Gotoh et al. 2007 ]. It certainly seems logical for a long-chain FA receptor regulating differentiation of cells whose function is to store energy as fat. FFAR1 is not expressed in adipocytes [Gotoh et al. 2007 ]. The major site of GPR120 expression is in the gastrointestinal tract where it is involved in FA sensing at various locations: work in rats has demonstrated a high level of expression in the taste buds of the tongue [Matsumura et al. 2009 [Matsumura et al. , 2007 . GPR120 expression has also been reported in pancreatic b cells, although this has not been a consistent finding [Morgan and Dhayal, 2009] . There is expression in the entero-endocrine cells (K cells) of the duodenum and jejunum where GPR120 is thought to regulate secretion of cholecystokinin (CCK) [Tanaka et al. 2008a ] and GIP [Parker et al. 2009; Tanaka et al. 2008b ]. In these cells, it is colocalized with FFAR1 and GPR119. GPR120 is the dominant long-chain FA receptor in the large intestine and regulates GLP-1 secretion from the L cells Katsuma et al. 2005 ]. We do not know what the most important natural ligands for GPR120 are but omega-3 FA appear to be active in this regard: a-linolenic acid is a potent stimulator of GLP-1 secretion [Tanaka et al. 2008b] , and colontargeted eicosapentaenoic acid and docosahexaenoic acid have also been shown to be potent GLP-1 secretagogues [Morishita et al. 2008] . The small molecule agonist G9508 activates GPR120 [Moore et al. 2009; Briscoe et al. 2006 ]. Other agonists have been identified from the screening of PPAR-g activators [Suzuki et al. 2008] and natural compounds including grifolic acid and its derivatives [Hara et al. 2009 ]. There are no compounds that have been shown to be of value as human pharmaceuticals at this stage.
GPR132 (G2A)
GPR132 is a stress-inducible receptor, expression of which is increased in lymphocytes on exposure of cells to DNA-damaging agents. Expression of the receptor is associated with a block in cell-cycle progression in the G2/M phase of the cycle (G2A ¼ G2 Accumulation) [Obinata et al. 2009 ]. Activation of the receptor leads to increased intracellular calcium and activation of kinases, including mitogen-activated protein kinases (particularly JNK). There has been considerable controversy regarding its pathophysiological role and its natural ligands. The highest expression is in leucocytes followed by the spleen, lung and heart. GPR132 is highly expressed in the macrophages of atherosclerotic plaque. Strong evidence has emerged that GPR132 functions as a receptor for oxidized FAs with 9-hydroxyoctadecadienoic acid (9-HODE) being the most potent ligand [Obinata et al. 2009 [Obinata et al. , 2005 Yin et al. 2009 ]. 9-HODE is an oxidized derivative of linoleic acid produced nonenzymatically in advanced atherosclerotic lesions. Regulation of chemotaxis and immune function through GPR132 is important in a variety of disease states caused by inflammation, infection or autoimmunity [Yang et al. 2005] .
A recent study provides evidence that 9-HODE is a pro-inflammatory mediator in the skin and that this action is mediated through GPR132 [Hattori et al. 2008] . The latter was expressed in normal human epidermal keratinocytes and in a keratinocyte line. Culture of the cells with 9-HODE led to increased intracellular calcium with inhibition of cell proliferation and increased secretion of inflammatory mediators.
GPR132 is expressed in the macrophages of atherosclerotic plaques, both in humans and experimental rabbits [Rikitake et al. 2002] . Genetic manipulation studies in mice have shed light on how GPR132 may contribute to the process of atherosclerosis. Bolick and colleagues used GPR132 knockout mice (G2 A À/À ) to study the interaction between monocytes and endothelial cells [Bolick et al. 2007 ]. The endothelial cells from GPR132-deficient mice showed increased intercellular adhesion molecule-1 and E-selectin expression, as well as secreting more interleukin (IL)-6 and monocyte chemotactic protein-1 compared with cells from control animals. Restoring GPR132 expression in knockout animals reversed the above changes and decreased monocyte interaction with endothelial cells. The conclusion from this study, which used animals with early atheroma, was that GPR132 was protective against atherosclerosis. A more recent study considered the effect of GPR132 deficiency in macrophages from apoE À/À mice [Bolick et al. 2009] . Macrophages from G2 A À/À animals had lower levels of apoptosis, a more pro-inflammatory M1 phenotype and decreased phagocytic activity. GPR132 deficiency was associated with an increase in size of the atherosclerotic lesions in the aortic root and increased numbers of infiltrating macrophages (presumably due to attenuated apoptosis).
Parks and colleagues used LDLR À/À mice fed a high-fat diet and demonstrated that loss of GPR132 was associated with increased macrophage accumulation, probably due to inhibition of apoptosis [Parks et al. 2005 ]. However, GPR132 deficiency attenuated lesion progression and was associated with lower numbers of intimal macrophages, and higher levels of high-density lipoprotein (HDL) cholesterol. Thus GPR132, in this animal model, appeared to have a detrimental effect on atherosclerosis. In a very recent study [Parks et al. 2009] , the pro-atherogenic effect of GPR132 was confirmed with G2 A À/À animals secreting more Apo1 and ApoE in their HDL fractions compared with control animals having normal GPR132. The study suggested that alterations in lipid status rather than monocyte chemotactic function were responsible for the apparent protective effect of GPR132 deficiency. The effect of GPR132 on hepatic lipid metabolism is consistent with another recent study, which showed that GPR132 activation may help to protect against gallstones [Johnson et al. 2008] . There are no published studies detailing pharmacological manipulation of GPR132 activity. Thus, studies to date confirm a role for GPR132 in atherosclerosis but beneficial pharmacological modulation of receptor activity will only be possible when the precise role of the receptor is better understood.
Conclusion
Nutrient-sensing GPRs are critical in the body's regulation of food intake and energy balance.
Receptors for FFAs have emerged as an important component of this apparatus and evidence is emerging that pharmacological manipulation of these pathways could contribute to the management of type 2 diabetes (Figure 2) . The controversy of whether FFAR1 agonists or antagonists might be beneficial is being resolved. Small molecule agonists may be useful as insulin secretagogues with direct actions on the b cell as well as indirect actions increasing secretion of incretins. Activation of FFAR2 decreases food intake by increasing peptide YY secretion. Short-chain FFAs have also been shown to increase adipogenesis, decrease lipolysis and increase leptin secretion through actions on short-chain FA receptors on adipocytes. A clearer understanding of the molecular species and mechanisms involved in the protective effects of short-chain FAs will lead to better probiotic, nutritional and pharmacological interventions. GPR119 agonists act as insulin secretagogues and several agents in this class have entered clinical trials. Their action is both direct on the b cell and indirectly by increasing GIP and GLP-1 secretion. In the latter, they synergize with dipeptidyl peptidase-IV inhibitors. GPR120 has roles in taste, incretin secretion and adipogenesis. Small molecule agonists have been identified. GPR132 is a receptor for oxidized lipids, which is expressed in the macrophages of advanced atherosclerotic lesions. It can be viewed as a sensor of lipid overload and oxidative stress, both of which are features of the diabetic state. While there are many uncertainties about the role of this receptor, it may well emerge as a therapeutic target in high-risk atherosclerosis-prone patients. In summary, FAs, through a series of recently described receptors, have important roles regulating insulin secretion, nutrient intake (through effects on incretins, CCK, peptide YY and leptin), as well as lipid storage and flux in adipose tissue. Targeting these signalling functions with small molecule agonists and antagonists is beginning to show considerable promise in helping us to prevent the rising burden of diabetes and its complications.
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